Anthropometric Injection Mask Selection for Precise Self-Administration

The patent applies parameter changes by offering a range of standard mask sizes (e.g., small, medium, large) with predetermined injection locations that can be selected based on patient anthropometric characteristics. This resolves the contradiction by adjusting the size parameter rather than customizing each mask individually, maintaining injection precision while reducing manufacturing complexity and cost.

The patent segments the patient population into different groups based on anthropometric characteristics (e.g., face size categories) and assigns specific standard mask sizes to each group. This segmentation approach allows standard masks with predetermined injection locations to serve multiple patients within each segment, eliminating the need for individual customization while maintaining adequate precision for each group.

The patent makes standard masks universal by designing them to fit multiple patients within specific anthropometric groups. Each standard mask size can be used across numerous patients with similar facial dimensions, eliminating the need for individual production while maintaining reliable treatment effectiveness through standardized injection location patterns validated for each size category.

The patent applies preliminary action by pre-configuring standard masks with predetermined injection locations during mass production. The injection sites are pre-marked and pre-positioned on each standard mask size based on anatomical studies, so that when a patient receives a mask, the injection locations are already optimized for their size group, eliminating the need for time-consuming customisation during treatment preparation.

The patent employs disposable pre-filled cartridges containing botulinum toxin that are single-use and disposed of after one injection session. This eliminates manual reconstitution entirely, as each cartridge is factory-sealed and pre-prepared with the exact drug concentration needed. The disposable nature ensures no contamination risk from repeated handling or reconstitution, while maintaining accurate drug delivery through factory-controlled filling processes.

The patent implements self-service through automated injection mechanisms where the device itself performs the drug delivery without requiring manual preparation by the clinician. The system includes integrated components that automatically advance the cartridge, position the needle, and deliver the precise dose, eliminating the need for manual reconstitution and reducing clinician exposure to contamination risks.